Drug industry and campaigners split over transparency of EU trials database
This article was originally published in SRA
Executive Summary
The consultation on transparency in the proposed EU clinical trials database has ended, and early signs suggest a clear if predictable split between the R&D-based industry, which wants tight strictures on what can be published and what should be deemed confidential, and transparency campaigners who say that confidentiality should be the exception rather than the norm1,2.